Our own developments


back


Greek mountain tea

Relevant studies on the CNS activity of Sideritis extracts

European Patent
"altered serotonergic neurotransmission"


European Patent ADHD








We have developed and patented extracts from Sideritis ssp. (Greek Mountain Tea), which have been shown in vitro to be triple monamine reuptake inhibitors. This pharmacological profile of Sideritis extracts suggests their use in the phytochemical therapy of mental disorders associated with a malfunctioning monoaminergic neurotransmission, like depressive disorders, panic attacs, generalised anxiety disorders or the attention-deficit 
hyperactivity disorder (ADHD). Sideritis extracts may be superior to other plant extract in the therapy of these disorders, since the long-term traditional use in the mediterranean area
until now did not reveal side effects of the drug. 

Several animal studies and observational studies with humans confirm this in vitro mechanism of action. You may find some studies relevant for the understanding of the CNS action of Sidertis extracts at the cross references on the left side.

We are convinced of the pharmaceutical potential of Sideritis extract as CNS drugs and search for interested cooperation partners to promote the development of innovative herbal medicines.